A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide Medication

What Was Tested

This registered phase 1 trial tested Semaglutide.

All participants will get semaglutide and zenagamtide.

It had 1 arm (groups): Semaglutide and Zenagamtide (experimental).

The registry classes the interventions as drug.

Who Took Part

The registry lists 60 planned participants were the target.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Male or female (sex assigned at birth, inclusive of all gender identities). Age 18 years or older at the time of signing the informed consent. Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator. Diagnosed with type 2 diabetes before screening.

The full record lists 6 inclusion and 13 exclusion criteria; among the exclusions: female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using adequate contraceptive method; use of prescription medicinal products or non-prescription drugs within 14 days before screening. exceptions are:; use of s.c. semaglutide as described in inclusion criterion 5.

How the Study Was Run

Design: sequential and open-label.

Nothing was hidden in this open-label Semaglutide study: the participants and staff both knew the treatment.

It started in 2026-10-05 with completion listed for 2028-09-06.

It ran at 2 sites in United States (2).

Its stated primary purpose is treatment.

What Was Measured

The main thing measured (primary outcome): Number of treatment emergent adverse events (TEAE) (time frame: From first administration of zenagamtide day 1 to day 57).

It also tracked 3 secondary outcomes, for example AUC: area under the zenagamtide plasma concentration-time curve.

What This Means in Plain Language

Put simply, this is a phase 1 trial of Semaglutide in 60 people.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, all human trials.